Rib-X Pharma delays IPO after price halved

Rib-X Pharmaceuticals, a New Haven, CT-based developer of antibiotics, opted to delay a planned May 9 initial public offering after chopping the price range of its shares for the maiden stock sale in half to $6 to $7, according to Renaissance Capital. Before postponing the IPO, Rib-X was aiming to raise $65 million in the offering. The biotech, a 2011 Fierce 15 company, is only the latest drug developer to struggle in its efforts to go public. Merrimack Pharmaceuticals ($MACK), also a 2011 Fierce 15 company, delayed an IPO before completing the offering earlier this year. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.